| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.3M | — | +577.0% |
| SG&A Expense | $3.3M | — | +592.5% |
| Operating Income | -$4.6M | — | -1755.6% |
| Net Income | -$4.6M | — | -2251.5% |
| EPS (Basic) | -$0.02 | — | -100.0% |
| EPS (Diluted) | -$0.02 | — | -100.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $103K | +415.0% | — |
| Current Assets | $1.2M | +104.5% | — |
| Total Assets | $2.0M | +46.3% | -78.5% |
| Current Liabilities | $10.4M | +2.1% | +32.2% |
| Total Liabilities | $27.3M | +23.5% | +154.2% |
| Stockholders' Equity | -$25.3M | -22.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.7M | — | -2239.4% |
| Financing Cash Flow | $2.8M | — | +2653.0% |
| -135.9% |